| CPAY |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$6.72 vs. cons $6.58 |
MEDIUM |
| CPAY |
Report |
Q2 2026 revenue |
IN-LINE |
pred ~$1.31B vs. cons $1.30B |
MEDIUM |
| CPAY |
Report |
Q2 2026 organic revenue growth |
BEAT |
pred ~11.2% vs. cons 10.2% |
MEDIUM |
| CPAY |
Guide |
FY 2026 revenue guidance |
BETTER |
guide ~$5.35B vs. cons $5.31B (FY 2026) |
MEDIUM |
| CPAY |
Guide |
FY 2026 adjusted EPS guidance |
BETTER |
guide ~$27.05 vs. cons $26.85 (FY 2026) |
MEDIUM |
| CPAY |
Guide |
FY 2026 organic revenue growth outlook |
UNCHANGED |
guide ~10.0% vs. cons 10.0% (FY 2026) |
MEDIUM |
| CPAY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
MEDIUM |
| CPAY |
Return |
5-day cumulative residual |
+5.5% (FOLLOW-THROUGH) |
A ~$0.14 Q2 EPS beat versus $6.58 consensus plus a ~$0.20 FY EPS-guide increase versus $26.85 consensus should drive upward out-period estimates; sustaining ~10.0% FY organic growth while raising reported revenue/EPS supports the Corporate Payments durability narrative rather than a purely fuel- or FX-driven beat. |
MEDIUM |